Nobody has tested PCT for RAD 140, the course of drugs given once exposure ends to restore endogenous production of testosterone, in a published study. The compound’s only human trial enrolled women with breast cancer, so it never measured testosterone in men, and no trial of a restart course has followed.
The question therefore has to be answered from thinner evidence than a reader might expect, and that evidence has three parts. A published case report recorded low testosterone and low output from the pituitary, and both normalised after the supplements containing RAD140 were withdrawn. Accounts outside the published studies describe marked suppression of testosterone and name anti-oestrogens as the means of reversing it, enclomiphene among them, which raises endogenous testosterone by blocking oestrogen receptors. And a review of the recovery drugs exists, written about men after anabolic steroids, not after RAD140. What supports recovery, in all of this, is the end of exposure, not any drug proven to restore the hormone.
Three names, one compound: testolone on the labels, RAD140 in the laboratory, vosilasarm in the breast cancer trials. The RAD 140 mechanism of action explains why the hormones fall at all. A selective androgen receptor modulator (SARM) stimulates the androgen receptor inside cells, the axis reads that stimulation as it would read testosterone and turns its own production down, and the compound’s selectivity between tissues is what carried it towards oncology rather than hormone research.
With no trial in men to answer “Does RAD 140 require PCT?”, this article takes the four tiers of evidence that do exist in turn, starting with the human trial and moving to the case report, the review of the recovery drugs and the accounts outside those studies. How any of these drugs are obtained or administered, and any effect on muscle mass, stay out.
Four tiers of evidence on recovery
Evidence
Who it covers
On suppression
On recovery
Phase 1 trial
22 women with metastatic breast cancer
SHBG and PSA only; no testosterone in men
Not measured
Case report
One man, 40, with products holding other hormones
Low testosterone and gonadotropins, not attributable to RAD140 alone
Normalised after stopping; time not given
Narrative review
Men after anabolic-androgenic steroids
Explains suppression of the axis by negative feedback
Varies between individuals; no standard treatment
Accounts outside published studies
First-person reports, products of unknown content
Marked suppression described
Weeks to months described, judged mostly by symptoms
Hormone markers in the only human trial
Every participant in the one human trial of RAD140 was a woman, which is the whole reason there is no direct reading of testosterone in men. The phase 1 trial escalated once-daily doses across three arms in postmenopausal women with ER+/HER2- metastatic breast cancer, oestrogen receptor-driven disease without HER2 amplification; the table below gives the doses and the number enrolled. In such a group the gonadotropins (LH and FSH), the luteinising and follicle-stimulating hormones with which the pituitary drives the testes in men, could show nothing, so the investigators fell back on two proteins in the blood as indirect evidence that the compound was engaging its target: serum sex hormone-binding globulin (SHBG), which fell in every participant tested, and prostate-specific antigen (PSA), which rose in most of those tested, at the counts the table below gives.
Androgens move both proteins in exactly those directions, and paired tumour biopsies confirmed that RAD140 had engaged the androgen receptor; how far the compound lowers the drive from the hypothalamus and pituitary to the testes is a question neither protein can answer. The trial left one more figure that touches recovery, an elimination half-life, whose value in the table below supported once-daily administration. Measured in women with advanced cancer at the trial’s doses, it says nothing about the depth of suppression in men or the time they take to recover.
What the phase 1 trial measured
Measure
Result
What it shows for recovery
Participants
22 postmenopausal women with ER+/HER2- metastatic breast cancer
Doses studied in women with advanced cancer, not a guide for anyone else
SHBG
Fell in 18 of 18
Moved as an androgen would move it
PSA
Rose in 16 of 20
Moved as an androgen would move it
Paired tumour biopsies
Androgen receptor engagement shown
Confirms target engagement, not axis suppression
Elimination half-life
44.7 hours
Slow elimination; no recovery time measured
Testosterone, LH, FSH in men
Not measured
Depth of suppression and time to recovery unknown
How the hypothalamus and pituitary respond to an androgen
Give the body an androgen from outside and the hypothalamus and pituitary turn down its own testosterone production. A 2026 review describes the lasting result, anabolic steroid-induced hypogonadism: low testosterone that persists after androgen exposure because the hypothalamic-pituitary-gonadal axis (the circuit from hypothalamus through pituitary to testes) has been suppressed for a long time. The gonadotropins carry the drive from the pituitary to the testes, and negative feedback, the braking action a hormone exerts on the signals that drive its own secretion, holds them low while the androgen is present.
Clomiphene citrate (Clomid) works the same circuit backwards. It is a selective oestrogen receptor modulator (SERM), and SERMs block oestrogen receptors in some tissues but not others; blocked at the hypothalamus and pituitary they stop relaying oestrogen’s brake, gonadotropin secretion rises and the testes are stimulated to make testosterone again. The review names drugs acting through that route as the ones pursued for recovery after androgen exposure, and enclomiphene as post-cycle therapy after a SARM rests on the same mechanism. Its data come from men after anabolic-androgenic steroids, so it explains how the drugs work and not how large the effect is after RAD140.
Suppression and breast growth in a published case report
The single published case of suppression is a 40-year-old man who, after six months of exposure to commercially sold supplements containing RAD-140, presented with bilateral gynaecomastia, enlarged breast tissue, and biochemical hypogonadotropic hypogonadism. The second finding is the telling one: hypogonadotropic hypogonadism means low testosterone with low gonadotropins, which places the fault in the hypothalamus or pituitary rather than in the testes.
The labels declared cardarine (a PPAR-delta agonist) and MK-677 (ibutamoren), a growth hormone secretagogue that prompts the pituitary to release growth hormone. In vitro analysis of all three products found what the labels did not say: testosterone, oestradiol and growth hormone itself, plus, on liquid chromatography–mass spectrometry, which separates compounds and identifies them by mass, an unidentified compound coeluting close to the testosterone peak. Exogenous testosterone and oestradiol suppress the hypothalamic-pituitary-gonadal axis on their own, so nothing in this one man’s record can be attributed to RAD140 alone.
Suppression and recovery as discussions describe them
Outside the published trials, no effect is attributed to RAD140 more consistently than suppression of endogenous testosterone, and a course of an oestrogen-blocking drug after exposure is its usual accompaniment. Among the effects described outside the trials the signs named most often are listed below, and the RAD-140 Reddit accounts among others describe coming off RAD 140 as followed by a dip in mood and drive before both settle.
reduced libido
low energy
low mood within the first weeks
a subjective reduction in testicular size in some accounts
In descriptions beyond the trials the suppression sets in quickly, and an oestrogen-blocking drug is often begun early in exposure rather than after it. The point argued most carefully is that such a drug offsets suppression only in part, for a reason of mechanism: enclomiphene acts on oestrogen feedback at the hypothalamus while RAD140 suppresses through androgen receptor feedback, so enclomiphene given during exposure leaves significant suppression in place.
Outside the trial record, some accounts describe recovery without any drug after short or low-dose exposures, others hold a restart course necessary in most cases, and all agree that a restart course has no place for as long as exogenous testosterone is being administered.
Do you need a PCT if you stop RAD140 after one week?
Among the effects described outside the trials, PCT after one week of exposure to RAD140 is held to be unlikely to be needed, though the accounts divide: a minority describe falls in libido and energy within days and favour either a short course of an oestrogen-blocking drug or a blood test before any further step.
Beyond the trial data the response named most often is a blood test of testosterone, LH and FSH a few weeks after exposure ends. Accounts outside the published studies describe an early end to exposure as followed within weeks by a return of energy without any drug, while a few describe a longer-lasting fall in drive; the reason exposure ended shapes the response, since adverse effects, doubts about a product’s content and a change of plan each draw a different one. Exposures of a few days come up far less often than the longer exposures that dominate the accounts as a whole.
MK-677 alongside RAD140 in the discussions
Outside the published trials, MK-677 is described as leaving the restart question after RAD140 unchanged, because it is a growth hormone secretagogue rather than an androgen: ibutamoren MK-677 acts at the ghrelin receptor, the receptor in the hypothalamus and pituitary for the appetite-regulating hormone ghrelin. In descriptions beyond the trials, MK-677 does not suppress testosterone, so a post-cycle course for RAD 140 and MK677 together is a matter of the androgen alone.
Accounts outside the published studies sometimes describe exposure to MK-677 as continuing into the restart period that follows the end of RAD140 exposure, with appetite and water retention the effects named over that period.
What the research says about clomiphene, tamoxifen and enclomiphene
What the best PCT for RAD 140 would be cannot be settled from published evidence, because no study has tested any drug as a restart course after exposure to the compound; clomiphene, enclomiphene and tamoxifen (Nolvadex, a SERM licensed for breast cancer) have been studied in recovery after anabolic-androgenic steroids instead. The nearest evidence is a 2026 narrative review of clomiphene citrate after steroid exposure, where the drug is used off-label, outside its licensed indication. The review finds no standardised treatment for anabolic steroid-induced hypogonadism; recovery, it reports, is frequently pursued with SERMs, with human chorionic gonadotropin (hCG), which stimulates the testes directly, and with aromatase inhibitors, which block the conversion of androgens to oestrogens.
Of those drugs clomiphene is the off-label medication used most often in that setting, with efficacy, safety and optimal monitoring that remain poorly defined. Lifting negative feedback, it raises gonadotropin secretion and endogenous testosterone while preserving spermatogenesis, and the clinical studies show hormonal parameters improving consistently; symptomatic recovery varies, and concerns remain over adverse metabolic effects and long-term efficacy.
CC is the most commonly employed off-label medication in ASIH, yet its clinical efficacy, safety and optimal monitoring strategies remain poorly defined.
The review names two emerging approaches that still lack validation in this population, kisspeptin analogues, peptides acting upstream of the gonadotropins, and enclomiphene, one of clomiphene’s two isomers (forms that share the same atoms but arrange them differently in space); the isomer is listed as enclomiphene for sale for laboratory research, with batch and purity data. Tamoxifen rests on weaker ground still, since a 2024 analysis records little clinically relevant data behind the off-label use of SERMs such as tamoxifen in this setting. Against all that evidence on the recovery drugs stands one figure from a study of RAD140 itself, the elimination half-life of 44.7 hours from the phase 1 trial.
Recovery drugs in the published research
Approach
How it acts
What the research finds
Tested after RAD140
Clomiphene citrate
Blocks oestrogen receptors, lifting negative feedback so gonadotropins rise
Little clinically relevant data behind off-label SERM use
No
hCG
Stimulates the testes directly
Frequently pursued; no standardised treatment exists
No
Aromatase inhibitors
Block conversion of androgens to oestrogens
Frequently pursued; no standardised treatment exists
No
Kisspeptin analogues
Act upstream of the gonadotropins
Emerging; lacks validation
No
Enclomiphene, tamoxifen or clomiphene as discussions describe them
In descriptions beyond the trials, enclomiphene is the drug named most often for restarting testosterone production after RAD140, tamoxifen close behind it and clomiphene well behind both. Many accounts describe enclomiphene during a SARM cycle, started during exposure, others describe it withheld until exposure ends, and a repeated argument weighs the two timings: enclomiphene blocks the negative feedback of oestrogen while RAD140 suppresses the axis through the androgen receptor, so enclomiphene given during exposure offsets the fall in testosterone only in part.
Outside the trial record, tamoxifen is described both as a restart drug in its own right and, more commonly, as a drug reserved for breast tenderness should it arise, and clomiphene as an alternative to enclomiphene, with mood swings and blurred vision the adverse effects attributed to it most often.
When the drugs are described as starting
Outside the trial record, a restart drug is described as started anywhere from the day after exposure ends to a week or more later; the slow elimination of RAD140 is the argument for a longer wait, and the interval named most often is a week to a fortnight.
Beyond the trial data, such a course runs to a few weeks and is extended where a blood test result is still low at its end, and enclomiphene begun partway through exposure and continued for some weeks after it ends is the pattern set out more fully than any other. The phase 1 trial measured the elimination half-life, but nothing in the trial record turns that figure into a rule for when such a course begins.
Is PCT the same as TRT?
Outside the trial record, PCT is described as working in the opposite direction to testosterone replacement therapy (TRT), the prescribed administration of testosterone for diagnosed hypogonadism: PCT tries to restart endogenous testosterone production once exposure to a suppressive compound has ended, while TRT supplies the hormone from outside under medical supervision. For as long as that supply continues, gonadotropin secretion from the pituitary stays turned down, and a restart course is meant to lift that same secretion.
Does a higher dose or longer exposure slow recovery after RAD140?
Accounts outside the published studies describe suppression of endogenous testosterone by an androgen as deepening with a higher dose and a longer exposure, and recovery as slower after such exposure than after a brief or modest one. The reasoning is simple: the more time the hypothalamic-pituitary drive to the testes has spent held down, the more time it is widely understood to need to return to its earlier level.
In those accounts individual factors shape the pace of that return as well, among them a man’s testosterone level before exposure, his age, and any other suppression of the axis at the same time. Any such comparison starts from the RAD140 dose actually administered and the length of exposure, both of which the published record sets out.
Recovery after stopping in the case reports and the review
In the published case report, ending exposure to the supplements containing RAD140 was enough: the hypogonadotropic hypogonadism normalised and the gynaecomastia resolved. The published summary names discontinuation of the products as the step taken and gives no time for the resolution, so the record establishes reversibility and nothing about its time course.
A second published case report concerns RAD140 and the liver (a different organ), and the table below sets the man’s age and length of exposure beside the first case. He developed jaundice and raised liver enzymes after exposure to RAD-140, an ultrasound scan of the liver showed hepatic steatosis and a hyperechoic lesion, and the symptoms resolved once exposure to the compound ended. Beyond these single cases, the LiverTox database devotes a monograph to SARMs and associates the class with cholestatic liver injury, in which impaired bile flow rather than damage to the hepatocytes themselves dominates the picture.
Declared MK-677 and cardarine; undisclosed testosterone, oestradiol and growth hormone
Full resolution; hormones normalised; time not given
Man, 29
RAD-140 for 3 months
Jaundice and raised liver enzymes; hepatic steatosis and a hyperechoic lesion on ultrasound
Not stated in the published summary
Symptoms resolved; time not given
On RAD 140 recovery more broadly, the 2026 review adds the qualification that matters most: the return of hormones after androgen exposure varies between individuals, and symptoms may lag even where hormonal parameters improve. That gap between improved blood values and how a man feels runs through the review’s reading of the clomiphene studies, and neither the gap nor its closing can be timed from the published work, because the review finds the best strategy for monitoring the return itself poorly defined.
How long do testosterone levels take to return to normal without PCT?
Outside the published trials, testosterone levels in the absence of PCT for RAD 140 are described as returning to normal within a few weeks to several months, more slowly after longer or higher-dose exposures; beyond the trial data the return is usually described only after exposure has ended, with no baseline measurement for comparison.
Accounts outside the published studies describe RAD-140 testosterone suppression recovery time as judged in most cases by energy and libido rather than by blood test results, and that reliance on symptoms explains why the ranges described are so wide. In descriptions beyond the trials, wherever blood was tested, testosterone and LH rose before energy and drive returned, so biochemical recovery runs ahead of symptomatic recovery.
Clinical studies consistently show improvements in hormonal parameters across different types of study participants, although symptomatic recovery varies
Can RAD140 lower natural testosterone permanently?
Where blood results after RAD140 are given outside the published trials, testosterone is described as returning over weeks to months in most cases; a smaller set describes values still low long after exposure ended, and a lasting change is the fear stated in them. In descriptions beyond the trials, the question does RAD 140 permanently lower testosterone recurs above all others, and the point most often set against it is whether testosterone was ever measured before exposure began.
Outside the trial record, a low LH beside a low testosterone is read as pointing to the brain and pituitary rather than to the testes as the site of the fault, and assessment by a doctor is the step named most frequently where values stay low, more often than any drug. Beyond the trial data, a sizeable set of accounts describes a restart course as unneeded after RAD140 at all, a view that sits against the accounts of marked suppression.
What if bloods are still low a long time after a cycle with no PCT?
Beyond the trial data, a consistent sequence of steps is described where blood hormone values stay low long after exposure to RAD140: a repeat test, LH and FSH measured alongside testosterone, and a doctor’s assessment before any drug. Exposure to RAD 140 with no PCT is described as ending in low values many months later, though comparatively rarely, and among the effects described outside the trials such a low value is weighed against other causes before it is attributed to the compound. Those causes are:
a mislabelled product
poor sleep
body weight
a testosterone level that may have been low before exposure began
Outside the published trials, blood tests taken months or years later are described in several cases as unremarkable, so a repeat test stands first among the steps named, and in descriptions beyond the trials values are described in a few cases as rising after a course of treatment led by a doctor.
Checking hormone recovery with blood tests
Recovery is checked by measuring testosterone together with the gonadotropins that drive its production, and the 2026 review warns that the measuring is harder than it looks: the limited specificity of immunoassays used by most routine laboratories complicates monitoring, and mass spectrometry is more reliable both for assessing hormonal recovery and for detecting residual androgen metabolites.
That second use matters here, because a residual androgen left over from exposure would distort a total testosterone result, which counts all testosterone in serum, bound and free alike. The review also finds the best strategy for monitoring recovery poorly defined, so no single panel or interval carries the weight of evidence; the pattern of RAD 140 blood work results can nevertheless be read whatever the method, since low testosterone with low gonadotropins places the fault in the hypothalamus and pituitary, and low testosterone with high gonadotropins in testes that fail to respond to the drive.
Why is testosterone higher than baseline after PCT?
Testosterone is generally held to rise above its baseline level while an oestrogen-blocking drug is acting, because such drugs lift gonadotropin secretion from the pituitary and with it the drive to the testes. The overshoot is widely understood to be an effect of the drug rather than a new set point for the axis, so the level is generally held to settle again once the drug is withdrawn and the negative feedback of oestrogen, no longer blocked, resumes its braking action.
Hidden hormones and low strength in products sold as RAD140
Products sold as RAD140 do not reliably contain what the label states, and that changes how any hormonal recovery recorded after exposure to them can be read. The supplements in the published case report held undisclosed testosterone, oestradiol and growth hormone beside the RAD-140, MK-677 and cardarine the labels declared, and Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products in a separate analysis and found them significantly under-dosed.
The two findings pull in opposite directions, and both obscure any hormonal change recorded after such products: undisclosed testosterone suppresses endogenous testosterone production in its own right, so suppression after such a product cannot be attributed to a SARM, while an under-dosed product leaves the actual exposure unknown. The document that tells the two cases apart is a certificate of analysis, and it is the same record that separates legit RAD 140 from the counterfeit products, under-dosed material and undisclosed hormones that testing has detected. The RAD-140 for sale here for laboratory research carries batch and purity data for each lot, and the UK SARMs range carries the same analytical data.
What a long mouse study of RAD140 recorded
A 10-week study gave young and adult female mice the SARM RAD140 at 5 mg/kg or a control solution, compared both treated groups with the controls and recorded no increase in strength. Frailty status, one of its measures, was expressed as a frailty index, a combination of signs of decline used to measure health span rather than lifespan alone.
In skeletal muscle the study also measured adaptive potential, muscle tissue’s capacity to adapt to repeated eccentric contractions, and torque after recovery from the contraction bouts; its findings are listed below. The study bears on the safety profile of RAD140 and not on hormonal recovery, because it measured strength and health span in female animals rather than hormones or testicular function.
higher frailty status in both treated groups than in the controls
higher mortality risk in both treated groups than in the controls
lower adaptive potential in the young animals alone
no difference in torque between groups after 2 to 3 weeks of recovery from the contraction bouts
Limits of the evidence on recovery after RAD140
Every tier of this evidence carries severe limits. The one human trial enrolled postmenopausal women with metastatic breast cancer and measured SHBG and PSA, so it gives no reading of testosterone in men; the case report describes one man, whose products contained other declared compounds and undisclosed hormones, so the contribution of RAD140 itself stays unresolved; the evidence on clomiphene and enclomiphene comes from recovery after anabolic-androgenic steroids and has not been validated for RAD140, nor, for enclomiphene, even for the steroid-exposed men the review describes; and the accounts outside the published studies are first-person descriptions of products of unknown content, given without measurement or follow-up.
[Figure 1. No study has tested recovery in men. Each published source cited here, placed by year and by the population it studied: women, mice, two single men, and steroid-exposed users. None measured hormone recovery in men after RAD140.]
Those accounts alone describe five points that no published study among this article’s sources has measured: early falls in libido and energy, recovery times without PCT for RAD 140, outcome after a one-week exposure, differences between enclomiphene, tamoxifen and clomiphene, and values described as still low long after exposure.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What limits the only human trial of RAD140 as evidence on testosterone in men?
It enrolled only postmenopausal women with breast cancer ✓
It measured hormones only by a routine laboratory immunoassay
It ended before any hormone samples were analysed
It enrolled only men already receiving testosterone therapy
The phase 1 trial enrolled 22 postmenopausal women with metastatic breast cancer and tracked SHBG and PSA, so it could give no reading of testosterone in men.
In the published case report, what leaves the source of the man's hormonal suppression unresolved?
The products also held undisclosed testosterone and oestradiol ✓
The man had low testosterone recorded before any exposure
The products held far less RAD140 than the label declared
The man was also receiving prescribed testosterone replacement therapy
Analysis found undisclosed testosterone, oestradiol and growth hormone in all three products, and these suppress the axis in their own right, so RAD140 alone cannot be blamed.
What does the 2026 review find when clomiphene is used for recovery after steroid exposure?
Hormone levels improve consistently, but symptomatic recovery varies ✓
Symptoms improve reliably, but hormone levels rarely rise at all
Hormones and symptoms both recover fully within a few weeks
Hormone levels improve only when hCG and an aromatase inhibitor are added
Clinical studies of clomiphene show consistent gains in hormonal parameters, yet how people feel recovers unevenly, and no study has tested it after RAD140.
On a blood test, what does low testosterone beside low LH and FSH point to?
A fault in the hypothalamus and pituitary ✓
Testes that fail to respond to the drive
A complete recovery from earlier suppression
An excess of oestrogen converted from androgens
Low testosterone with low gonadotropins places the fault upstream in the hypothalamus and pituitary, while high gonadotropins would point to the testes.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
RAD 140 suppression and recovery: what the evidence shows
By Elizabeth Hyams · Reviewed by Bonnie Grant, MBBS
Published · Updated · 22 min read
Hormone recovery after RAD140: the short answer
Nobody has tested PCT for RAD 140, the course of drugs given once exposure ends to restore endogenous production of testosterone, in a published study. The compound’s only human trial enrolled women with breast cancer, so it never measured testosterone in men, and no trial of a restart course has followed.
The question therefore has to be answered from thinner evidence than a reader might expect, and that evidence has three parts. A published case report recorded low testosterone and low output from the pituitary, and both normalised after the supplements containing RAD140 were withdrawn. Accounts outside the published studies describe marked suppression of testosterone and name anti-oestrogens as the means of reversing it, enclomiphene among them, which raises endogenous testosterone by blocking oestrogen receptors. And a review of the recovery drugs exists, written about men after anabolic steroids, not after RAD140. What supports recovery, in all of this, is the end of exposure, not any drug proven to restore the hormone.
Three names, one compound: testolone on the labels, RAD140 in the laboratory, vosilasarm in the breast cancer trials. The RAD 140 mechanism of action explains why the hormones fall at all. A selective androgen receptor modulator (SARM) stimulates the androgen receptor inside cells, the axis reads that stimulation as it would read testosterone and turns its own production down, and the compound’s selectivity between tissues is what carried it towards oncology rather than hormone research.
With no trial in men to answer “Does RAD 140 require PCT?”, this article takes the four tiers of evidence that do exist in turn, starting with the human trial and moving to the case report, the review of the recovery drugs and the accounts outside those studies. How any of these drugs are obtained or administered, and any effect on muscle mass, stay out.
Four tiers of evidence on recovery
Hormone markers in the only human trial
Every participant in the one human trial of RAD140 was a woman, which is the whole reason there is no direct reading of testosterone in men. The phase 1 trial escalated once-daily doses across three arms in postmenopausal women with ER+/HER2- metastatic breast cancer, oestrogen receptor-driven disease without HER2 amplification; the table below gives the doses and the number enrolled. In such a group the gonadotropins (LH and FSH), the luteinising and follicle-stimulating hormones with which the pituitary drives the testes in men, could show nothing, so the investigators fell back on two proteins in the blood as indirect evidence that the compound was engaging its target: serum sex hormone-binding globulin (SHBG), which fell in every participant tested, and prostate-specific antigen (PSA), which rose in most of those tested, at the counts the table below gives.
Androgens move both proteins in exactly those directions, and paired tumour biopsies confirmed that RAD140 had engaged the androgen receptor; how far the compound lowers the drive from the hypothalamus and pituitary to the testes is a question neither protein can answer. The trial left one more figure that touches recovery, an elimination half-life, whose value in the table below supported once-daily administration. Measured in women with advanced cancer at the trial’s doses, it says nothing about the depth of suppression in men or the time they take to recover.
What the phase 1 trial measured
How the hypothalamus and pituitary respond to an androgen
Give the body an androgen from outside and the hypothalamus and pituitary turn down its own testosterone production. A 2026 review describes the lasting result, anabolic steroid-induced hypogonadism: low testosterone that persists after androgen exposure because the hypothalamic-pituitary-gonadal axis (the circuit from hypothalamus through pituitary to testes) has been suppressed for a long time. The gonadotropins carry the drive from the pituitary to the testes, and negative feedback, the braking action a hormone exerts on the signals that drive its own secretion, holds them low while the androgen is present.
Clomiphene citrate (Clomid) works the same circuit backwards. It is a selective oestrogen receptor modulator (SERM), and SERMs block oestrogen receptors in some tissues but not others; blocked at the hypothalamus and pituitary they stop relaying oestrogen’s brake, gonadotropin secretion rises and the testes are stimulated to make testosterone again. The review names drugs acting through that route as the ones pursued for recovery after androgen exposure, and enclomiphene as post-cycle therapy after a SARM rests on the same mechanism. Its data come from men after anabolic-androgenic steroids, so it explains how the drugs work and not how large the effect is after RAD140.
Suppression and breast growth in a published case report
The single published case of suppression is a 40-year-old man who, after six months of exposure to commercially sold supplements containing RAD-140, presented with bilateral gynaecomastia, enlarged breast tissue, and biochemical hypogonadotropic hypogonadism. The second finding is the telling one: hypogonadotropic hypogonadism means low testosterone with low gonadotropins, which places the fault in the hypothalamus or pituitary rather than in the testes.
The labels declared cardarine (a PPAR-delta agonist) and MK-677 (ibutamoren), a growth hormone secretagogue that prompts the pituitary to release growth hormone. In vitro analysis of all three products found what the labels did not say: testosterone, oestradiol and growth hormone itself, plus, on liquid chromatography–mass spectrometry, which separates compounds and identifies them by mass, an unidentified compound coeluting close to the testosterone peak. Exogenous testosterone and oestradiol suppress the hypothalamic-pituitary-gonadal axis on their own, so nothing in this one man’s record can be attributed to RAD140 alone.
Suppression and recovery as discussions describe them
Outside the published trials, no effect is attributed to RAD140 more consistently than suppression of endogenous testosterone, and a course of an oestrogen-blocking drug after exposure is its usual accompaniment. Among the effects described outside the trials the signs named most often are listed below, and the RAD-140 Reddit accounts among others describe coming off RAD 140 as followed by a dip in mood and drive before both settle.
In descriptions beyond the trials the suppression sets in quickly, and an oestrogen-blocking drug is often begun early in exposure rather than after it. The point argued most carefully is that such a drug offsets suppression only in part, for a reason of mechanism: enclomiphene acts on oestrogen feedback at the hypothalamus while RAD140 suppresses through androgen receptor feedback, so enclomiphene given during exposure leaves significant suppression in place.
Outside the trial record, some accounts describe recovery without any drug after short or low-dose exposures, others hold a restart course necessary in most cases, and all agree that a restart course has no place for as long as exogenous testosterone is being administered.
Do you need a PCT if you stop RAD140 after one week?
Among the effects described outside the trials, PCT after one week of exposure to RAD140 is held to be unlikely to be needed, though the accounts divide: a minority describe falls in libido and energy within days and favour either a short course of an oestrogen-blocking drug or a blood test before any further step.
Beyond the trial data the response named most often is a blood test of testosterone, LH and FSH a few weeks after exposure ends. Accounts outside the published studies describe an early end to exposure as followed within weeks by a return of energy without any drug, while a few describe a longer-lasting fall in drive; the reason exposure ended shapes the response, since adverse effects, doubts about a product’s content and a change of plan each draw a different one. Exposures of a few days come up far less often than the longer exposures that dominate the accounts as a whole.
MK-677 alongside RAD140 in the discussions
Outside the published trials, MK-677 is described as leaving the restart question after RAD140 unchanged, because it is a growth hormone secretagogue rather than an androgen: ibutamoren MK-677 acts at the ghrelin receptor, the receptor in the hypothalamus and pituitary for the appetite-regulating hormone ghrelin. In descriptions beyond the trials, MK-677 does not suppress testosterone, so a post-cycle course for RAD 140 and MK677 together is a matter of the androgen alone.
Accounts outside the published studies sometimes describe exposure to MK-677 as continuing into the restart period that follows the end of RAD140 exposure, with appetite and water retention the effects named over that period.
What the research says about clomiphene, tamoxifen and enclomiphene
What the best PCT for RAD 140 would be cannot be settled from published evidence, because no study has tested any drug as a restart course after exposure to the compound; clomiphene, enclomiphene and tamoxifen (Nolvadex, a SERM licensed for breast cancer) have been studied in recovery after anabolic-androgenic steroids instead. The nearest evidence is a 2026 narrative review of clomiphene citrate after steroid exposure, where the drug is used off-label, outside its licensed indication. The review finds no standardised treatment for anabolic steroid-induced hypogonadism; recovery, it reports, is frequently pursued with SERMs, with human chorionic gonadotropin (hCG), which stimulates the testes directly, and with aromatase inhibitors, which block the conversion of androgens to oestrogens.
Of those drugs clomiphene is the off-label medication used most often in that setting, with efficacy, safety and optimal monitoring that remain poorly defined. Lifting negative feedback, it raises gonadotropin secretion and endogenous testosterone while preserving spermatogenesis, and the clinical studies show hormonal parameters improving consistently; symptomatic recovery varies, and concerns remain over adverse metabolic effects and long-term efficacy.
The review names two emerging approaches that still lack validation in this population, kisspeptin analogues, peptides acting upstream of the gonadotropins, and enclomiphene, one of clomiphene’s two isomers (forms that share the same atoms but arrange them differently in space); the isomer is listed as enclomiphene for sale for laboratory research, with batch and purity data. Tamoxifen rests on weaker ground still, since a 2024 analysis records little clinically relevant data behind the off-label use of SERMs such as tamoxifen in this setting. Against all that evidence on the recovery drugs stands one figure from a study of RAD140 itself, the elimination half-life of 44.7 hours from the phase 1 trial.
Recovery drugs in the published research
Enclomiphene, tamoxifen or clomiphene as discussions describe them
In descriptions beyond the trials, enclomiphene is the drug named most often for restarting testosterone production after RAD140, tamoxifen close behind it and clomiphene well behind both. Many accounts describe enclomiphene during a SARM cycle, started during exposure, others describe it withheld until exposure ends, and a repeated argument weighs the two timings: enclomiphene blocks the negative feedback of oestrogen while RAD140 suppresses the axis through the androgen receptor, so enclomiphene given during exposure offsets the fall in testosterone only in part.
Outside the trial record, tamoxifen is described both as a restart drug in its own right and, more commonly, as a drug reserved for breast tenderness should it arise, and clomiphene as an alternative to enclomiphene, with mood swings and blurred vision the adverse effects attributed to it most often.
When the drugs are described as starting
Outside the trial record, a restart drug is described as started anywhere from the day after exposure ends to a week or more later; the slow elimination of RAD140 is the argument for a longer wait, and the interval named most often is a week to a fortnight.
Beyond the trial data, such a course runs to a few weeks and is extended where a blood test result is still low at its end, and enclomiphene begun partway through exposure and continued for some weeks after it ends is the pattern set out more fully than any other. The phase 1 trial measured the elimination half-life, but nothing in the trial record turns that figure into a rule for when such a course begins.
Is PCT the same as TRT?
Outside the trial record, PCT is described as working in the opposite direction to testosterone replacement therapy (TRT), the prescribed administration of testosterone for diagnosed hypogonadism: PCT tries to restart endogenous testosterone production once exposure to a suppressive compound has ended, while TRT supplies the hormone from outside under medical supervision. For as long as that supply continues, gonadotropin secretion from the pituitary stays turned down, and a restart course is meant to lift that same secretion.
Does a higher dose or longer exposure slow recovery after RAD140?
Accounts outside the published studies describe suppression of endogenous testosterone by an androgen as deepening with a higher dose and a longer exposure, and recovery as slower after such exposure than after a brief or modest one. The reasoning is simple: the more time the hypothalamic-pituitary drive to the testes has spent held down, the more time it is widely understood to need to return to its earlier level.
In those accounts individual factors shape the pace of that return as well, among them a man’s testosterone level before exposure, his age, and any other suppression of the axis at the same time. Any such comparison starts from the RAD140 dose actually administered and the length of exposure, both of which the published record sets out.
Recovery after stopping in the case reports and the review
In the published case report, ending exposure to the supplements containing RAD140 was enough: the hypogonadotropic hypogonadism normalised and the gynaecomastia resolved. The published summary names discontinuation of the products as the step taken and gives no time for the resolution, so the record establishes reversibility and nothing about its time course.
A second published case report concerns RAD140 and the liver (a different organ), and the table below sets the man’s age and length of exposure beside the first case. He developed jaundice and raised liver enzymes after exposure to RAD-140, an ultrasound scan of the liver showed hepatic steatosis and a hyperechoic lesion, and the symptoms resolved once exposure to the compound ended. Beyond these single cases, the LiverTox database devotes a monograph to SARMs and associates the class with cholestatic liver injury, in which impaired bile flow rather than damage to the hepatocytes themselves dominates the picture.
Two published RAD140 case reports
On RAD 140 recovery more broadly, the 2026 review adds the qualification that matters most: the return of hormones after androgen exposure varies between individuals, and symptoms may lag even where hormonal parameters improve. That gap between improved blood values and how a man feels runs through the review’s reading of the clomiphene studies, and neither the gap nor its closing can be timed from the published work, because the review finds the best strategy for monitoring the return itself poorly defined.
How long do testosterone levels take to return to normal without PCT?
Outside the published trials, testosterone levels in the absence of PCT for RAD 140 are described as returning to normal within a few weeks to several months, more slowly after longer or higher-dose exposures; beyond the trial data the return is usually described only after exposure has ended, with no baseline measurement for comparison.
Accounts outside the published studies describe RAD-140 testosterone suppression recovery time as judged in most cases by energy and libido rather than by blood test results, and that reliance on symptoms explains why the ranges described are so wide. In descriptions beyond the trials, wherever blood was tested, testosterone and LH rose before energy and drive returned, so biochemical recovery runs ahead of symptomatic recovery.
Can RAD140 lower natural testosterone permanently?
Where blood results after RAD140 are given outside the published trials, testosterone is described as returning over weeks to months in most cases; a smaller set describes values still low long after exposure ended, and a lasting change is the fear stated in them. In descriptions beyond the trials, the question does RAD 140 permanently lower testosterone recurs above all others, and the point most often set against it is whether testosterone was ever measured before exposure began.
Outside the trial record, a low LH beside a low testosterone is read as pointing to the brain and pituitary rather than to the testes as the site of the fault, and assessment by a doctor is the step named most frequently where values stay low, more often than any drug. Beyond the trial data, a sizeable set of accounts describes a restart course as unneeded after RAD140 at all, a view that sits against the accounts of marked suppression.
What if bloods are still low a long time after a cycle with no PCT?
Beyond the trial data, a consistent sequence of steps is described where blood hormone values stay low long after exposure to RAD140: a repeat test, LH and FSH measured alongside testosterone, and a doctor’s assessment before any drug. Exposure to RAD 140 with no PCT is described as ending in low values many months later, though comparatively rarely, and among the effects described outside the trials such a low value is weighed against other causes before it is attributed to the compound. Those causes are:
Outside the published trials, blood tests taken months or years later are described in several cases as unremarkable, so a repeat test stands first among the steps named, and in descriptions beyond the trials values are described in a few cases as rising after a course of treatment led by a doctor.
Checking hormone recovery with blood tests
Recovery is checked by measuring testosterone together with the gonadotropins that drive its production, and the 2026 review warns that the measuring is harder than it looks: the limited specificity of immunoassays used by most routine laboratories complicates monitoring, and mass spectrometry is more reliable both for assessing hormonal recovery and for detecting residual androgen metabolites.
That second use matters here, because a residual androgen left over from exposure would distort a total testosterone result, which counts all testosterone in serum, bound and free alike. The review also finds the best strategy for monitoring recovery poorly defined, so no single panel or interval carries the weight of evidence; the pattern of RAD 140 blood work results can nevertheless be read whatever the method, since low testosterone with low gonadotropins places the fault in the hypothalamus and pituitary, and low testosterone with high gonadotropins in testes that fail to respond to the drive.
Why is testosterone higher than baseline after PCT?
Testosterone is generally held to rise above its baseline level while an oestrogen-blocking drug is acting, because such drugs lift gonadotropin secretion from the pituitary and with it the drive to the testes. The overshoot is widely understood to be an effect of the drug rather than a new set point for the axis, so the level is generally held to settle again once the drug is withdrawn and the negative feedback of oestrogen, no longer blocked, resumes its braking action.
Hidden hormones and low strength in products sold as RAD140
Products sold as RAD140 do not reliably contain what the label states, and that changes how any hormonal recovery recorded after exposure to them can be read. The supplements in the published case report held undisclosed testosterone, oestradiol and growth hormone beside the RAD-140, MK-677 and cardarine the labels declared, and Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products in a separate analysis and found them significantly under-dosed.
The two findings pull in opposite directions, and both obscure any hormonal change recorded after such products: undisclosed testosterone suppresses endogenous testosterone production in its own right, so suppression after such a product cannot be attributed to a SARM, while an under-dosed product leaves the actual exposure unknown. The document that tells the two cases apart is a certificate of analysis, and it is the same record that separates legit RAD 140 from the counterfeit products, under-dosed material and undisclosed hormones that testing has detected. The RAD-140 for sale here for laboratory research carries batch and purity data for each lot, and the UK SARMs range carries the same analytical data.
What a long mouse study of RAD140 recorded
A 10-week study gave young and adult female mice the SARM RAD140 at 5 mg/kg or a control solution, compared both treated groups with the controls and recorded no increase in strength. Frailty status, one of its measures, was expressed as a frailty index, a combination of signs of decline used to measure health span rather than lifespan alone.
In skeletal muscle the study also measured adaptive potential, muscle tissue’s capacity to adapt to repeated eccentric contractions, and torque after recovery from the contraction bouts; its findings are listed below. The study bears on the safety profile of RAD140 and not on hormonal recovery, because it measured strength and health span in female animals rather than hormones or testicular function.
Limits of the evidence on recovery after RAD140
Every tier of this evidence carries severe limits. The one human trial enrolled postmenopausal women with metastatic breast cancer and measured SHBG and PSA, so it gives no reading of testosterone in men; the case report describes one man, whose products contained other declared compounds and undisclosed hormones, so the contribution of RAD140 itself stays unresolved; the evidence on clomiphene and enclomiphene comes from recovery after anabolic-androgenic steroids and has not been validated for RAD140, nor, for enclomiphene, even for the steroid-exposed men the review describes; and the accounts outside the published studies are first-person descriptions of products of unknown content, given without measurement or follow-up.
Those accounts alone describe five points that no published study among this article’s sources has measured: early falls in libido and energy, recovery times without PCT for RAD 140, outcome after a one-week exposure, differences between enclomiphene, tamoxifen and clomiphene, and values described as still low long after exposure.
Check what you remember
4 questions on this article; the right answer is marked.
The phase 1 trial enrolled 22 postmenopausal women with metastatic breast cancer and tracked SHBG and PSA, so it could give no reading of testosterone in men.
Analysis found undisclosed testosterone, oestradiol and growth hormone in all three products, and these suppress the axis in their own right, so RAD140 alone cannot be blamed.
Clinical studies of clomiphene show consistent gains in hormonal parameters, yet how people feel recovers unevenly, and no study has tested it after RAD140.
Low testosterone with low gonadotropins places the fault upstream in the hypothalamus and pituitary, while high gonadotropins would point to the testes.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Bonnie Grant, MBBS · Imperial College London · Last reviewed
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
Related Posts
RAD 140 half life: the trial figure, timing and onset
The RAD 140 half life measured in its one human trial was about 44.7 hours, the figure behind once-daily administration in women with breast cancer.
RAD140 dose: what the trials gave and the evidence covers
No RAD140 dose is approved: its dose-finding trial gave 50, 100 or 150 mg daily in breast cancer, and a later vosilasarm study gave 10 mg twice daily.
Ostarine course length: trial durations and what is reported
ostarine cycle length in the enobosarm trials ran 86 to 147 days once daily, while published liver injury cases followed about six weeks of exposure.